Metastatic Melanoma - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 648
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M9F293634BFEN
Leaflet:

Download PDF Leaflet

Metastatic Melanoma - Pipeline Review, H2 2016
Metastatic Melanoma - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Metastatic Melanoma - Pipeline Review, H2 2016’, provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
  • The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Metastatic Melanoma Overview
Therapeutics Development
Metastatic Melanoma - Therapeutics under Development by Companies
Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes
Metastatic Melanoma - Pipeline Products Glance
Metastatic Melanoma - Products under Development by Companies
Metastatic Melanoma - Products under Investigation by Universities/Institutes
Metastatic Melanoma - Companies Involved in Therapeutics Development
Metastatic Melanoma - Therapeutics Assessment
Drug Profiles
Metastatic Melanoma - Dormant Projects
Metastatic Melanoma - Discontinued Products
Metastatic Melanoma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Metastatic Melanoma, H2 2016
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Development by Companies, H2 2016 (Contd.4)
Number of Products under Development by Companies, H2 2016 (Contd.5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Development by Companies, H2 2016 (Contd.6)
Products under Development by Companies, H2 2016 (Contd.7)
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Melanoma - Pipeline by AB Science SA, H2 2016
Metastatic Melanoma - Pipeline by AbbVie Inc, H2 2016
Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Metastatic Melanoma - Pipeline by Affichem SA, H2 2016
Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2016
Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H2 2016
Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H2 2016
Metastatic Melanoma - Pipeline by Amgen Inc., H2 2016
Metastatic Melanoma - Pipeline by Angimmune LLC, H2 2016
Metastatic Melanoma - Pipeline by Apexigen, Inc., H2 2016
Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by Array BioPharma Inc., H2 2016
Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by AstraZeneca Plc, H2 2016
Metastatic Melanoma - Pipeline by Basilea Pharmaceutica Ltd., H2 2016
Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by BerGenBio AS, H2 2016
Metastatic Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016
Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2016
Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Metastatic Melanoma - Pipeline by Calithera Biosciences, Inc., H2 2016
Metastatic Melanoma - Pipeline by Cellceutix Corporation, H2 2016
Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H2 2016
Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2016
Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2016
Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2016
Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2016
Metastatic Melanoma - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H2 2016
Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Metastatic Melanoma - Pipeline by Galapagos NV, H2 2016
Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2016
Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by Ignyta, Inc., H2 2016
Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2016
Metastatic Melanoma - Pipeline by Immunocore Limited, H2 2016
Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2016
Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2016
Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by IO Biotech ApS, H2 2016
Metastatic Melanoma - Pipeline by Lentigen Technology, Inc., H2 2016
Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2016
Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2016
Metastatic Melanoma - Pipeline by MacroGenics, Inc., H2 2016
Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2016
Metastatic Melanoma - Pipeline by Medivation, Inc., H2 2016
Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH, H2 2016
Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2016
Metastatic Melanoma - Pipeline by Merck KGaA, H2 2016
Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H2 2016
Metastatic Melanoma - Pipeline by Moleculin Biotech Inc, H2 2016
Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2016
Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H2 2016
Metastatic Melanoma - Pipeline by Novartis AG, H2 2016
Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2016
Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2016
Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H2 2016
Metastatic Melanoma - Pipeline by Onxeo SA, H2 2016
Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2016
Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H2 2016
Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2016
Metastatic Melanoma - Pipeline by PinCell srl, H2 2016
Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2016
Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H2 2016
Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H2 2016
Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H2 2016
Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2016
Metastatic Melanoma - Pipeline by Sillajen Biotherapeutics, H2 2016
Metastatic Melanoma - Pipeline by SolaranRx, Inc., H2 2016
Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2016
Metastatic Melanoma - Pipeline by TC BioPharm Limited, H2 2016
Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H2 2016
Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Melanoma - Dormant Projects, H2 2016
Metastatic Melanoma - Dormant Projects (Contd.1), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.2), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.3), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.4), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.5), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.6), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.7), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.8), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.9), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.10), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.11), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.12), H2 2016
Metastatic Melanoma - Dormant Projects (Contd.13), H2 2016
Metastatic Melanoma - Discontinued Products, H2 2016
Metastatic Melanoma - Discontinued Products (Contd.1), H2 2016

LIST OF FIGURES

Number of Products under Development for Metastatic Melanoma, H2 2016
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

AB Science SA
AbbVie Inc
Adaptimmune Therapeutics Plc
Affichem SA
Agalimmune Ltd
AGV Discovery, SAS
Altor BioScience Corporation
Amgen Inc.
Angimmune LLC
Apexigen, Inc.
Arisaph Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Basilea Pharmaceutica Ltd.
Bellicum Pharmaceuticals, Inc.
BerGenBio AS
Bioncotech Therapeutics SL
Bionomics Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cortice Biosciences, Inc.
Delcath Systems, Inc.
Digna Biotech, S.L.
Dynavax Technologies Corporation
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
F. Hoffmann-La Roche Ltd.
Galapagos NV
Galectin Therapeutics, Inc.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
Ignyta, Inc.
Immune Design Corp.
Immunocore Limited
ImmuRx, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
IO Biotech ApS
Lentigen Technology, Inc.
Life Science Pharmaceuticals, Incorporated
Lipotek Pty Ltd.
MacroGenics, Inc.
MedImmune, LLC
Medivation, Inc.
MELEMA Pharma GmbH
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Modulate Therapeutics, Inc.
Moleculin Biotech Inc
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Incorporated
Onxeo SA
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
PinCell srl
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Prima BioMed Ltd.
Provectus Biopharmaceuticals, Inc.
Provenance Biopharmaceuticals Corp.
Reata Pharmaceuticals, Inc.
Recepta Biopharma S.A.
RXi Pharmaceuticals Corporation
Scancell Holdings Plc
Sillajen Biotherapeutics
SolaranRx, Inc.
Syndax Pharmaceuticals Inc
Takara Bio Inc.
TC BioPharm Limited
Tikcro Technologies, Ltd.
Ultimovacs AS
Skip to top


Melanoma - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1508 pages

Ask Your Question

Metastatic Melanoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: